Early-phase oncology trials are designed around what we know at the start—but new information emerges quickly. Here’s why adaptation is often part of the process.

Oncology protocols can be exceptionally complex. Here’s what drives that complexity—and why much of it is necessary to safely answer the questions a trial is designed to address.

SAEs and SUSARs are both critical to clinical trial safety—but they’re not the same thing. Here’s how they differ and why the distinction matters.